Release Date: July 25, 2025

Expiration Date: July 25, 2026

Activity Overview

This educational activity is an archive of the live virtual presentation held on Thursday, June 12, 2025.

For more information about this educational activity, the faculty, and disclosures, please click here.

Target Audience

This educational program is directed toward attendees of the 2025 European Hematology Association (EHA) Congress. These include a global audience of oncologists, hematologist/oncologists, hematologists, and hematopathologists involved in diagnosing and managing patients with newly diagnosed multiple myeloma (NDMM).

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Evaluate efficacy and safety outcomes from recent clinical trials in patients with NDMM
Individualize therapy for patients with NDMM based on recent evidence and clinical guidelines
Implement strategies to address treatment-related adverse events in patients with NDMM
Discuss the role of MRD assessments for guiding therapy in patients with NDMM

Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma

GET STARTED WITH THIS PROGRAM:

Create Account Already Registered? Login Here

Accreditation/Credit Designation

Physicians’ Education Resource^®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Sanofi.

Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma

GET STARTED WITH THIS PROGRAM:

Related Content